Subjects treated with OTX-TIC demonstrated a mean reduction in IOP from baseline of 7 mm Hg to 11 mm Hg as early as 2 days after administration, according to interim phase 1 clinical trial results presented by Ocular Therapeutix.
“OTX-TIC was developed to deliver travoprost for an extended duration of time and, if shown to be safe and effective, represents a possible solution to this problem. Continued long-term evaluation is ongoing, but we are very excited by what we have seen with the early results from this trial,” Michael Goldstein, (Read more...)
Uncategorized